10 unknown, 8 completed, 8 recruiting, 3 terminated. 19 Phase 2, 4 Not applicable, 3 Phase 3, 2 Phase 1, 2 Phase 4.
Follow Non-small Cell Lung Cancer Stage III: new trials by email Literature Review of Non-small Cell Lung Cancer Stage III trials Research Report on Non-small Cell Lung Cancer Stage III
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features Cemiplimab-Rwlc - Non-small Cell Lung Cancer Stage III | Phase 2 | Recruiting | Georgetown University | 21 | 2026-11-01 | 2026-10-06 |
| A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) BL-B01D1, Osimertinib - Non-small Cell Lung Cancer Stage III | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 418 | 2026-08-28 | 2026-09-10 |
| Pulmonary Rehabilitation in Advanced Lung Cancer Survivors Pulmonary Rehabilitation (PR), No intervention: Usual care - Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 85 | 2026-03-16 | 2026-09-22 |
| Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC Durvalumab - Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma | Phase 2 | Not yet recruiting | Bi Nan | 80 | 2025-07-01 | 2025-05-31 |
| Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab Consolidation durvalumab - Non-small Cell Lung Cancer Stage III | Phase 4 | Recruiting | Idris Bahce | 38 | 2024-12-17 | 2026-08-20 |
| Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients Durvalumab - Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation | Recruiting | Fundación GECP | 50 | 2024-10-03 | 2026-01-28 | |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC - Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma | Phase 2 | Recruiting | Genelux Corporation | 142 | 2024-09-26 | 2026-06-04 |
| Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab - Non-small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Alexander Chi | 83 | 2023-10-09 | 2023-10-03 |
| Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy radiotherapy, Platinum-Based Drug, Immunotherapy - Non-small Cell Lung Cancer Stage III | Phase 3 | Unknown | Zhejiang Cancer Hospital | 105 | 2023-09-15 | 2023-09-13 |
| Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Photon, Proton - Non-small Cell Lung Cancer Stage III, Radiotherapy Side Effect | Phase 2 | Not yet recruiting | Odense University Hospital | 182 | 2022-10-01 | 2022-09-21 |
| Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer standar thoracic RT dose, decreased thoracic RT dose - Non-small Cell Lung Cancer Stage III | Not applicable | Unknown | Ruijin Hospital | 56 | 2022-09-30 | 2024-09-23 |
| Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer Sintilimab, Chemotherapy - Non-small Cell Lung Cancer Stage III | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2022-09-10 | 2023-09-13 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy single arm - Metastatic Melanoma, Metastatic Breast Cancer | Not applicable | Withdrawn | Institut du Cancer de Montpellier - Val d'Aurelle | 2022-07-07 | 2022-12-22 | |
| A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Lazertinib - Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Unknown | Sung Yong Lee | 77 | 2022-06-30 | 2023-09-01 |
| A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer Envafolimab - Non-small Cell Lung Cancer Stage III | Phase 2 | Unknown | Anhui Provincial Cancer Hospital | 30 | 2022-06-01 | 2022-06-10 |
| Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy Sotorasib - Non-small Cell Lung Cancer Stage III, KRAS P.G12C | Phase 2 | Recruiting | Fundación GECP | 19 | 2022-03-21 | 2026-04-30 |
| Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer HS-10296 (Almonertinib) - Non-small Cell Lung Cancer Stage III | Phase 2 | Active not recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 56 | 2021-12-14 | 2024-08-14 |
| Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed), Durvalumab plus radiotherapy, durvalumab - Non-small Cell Lung Cancer Stage III | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 10 | 2021-09-24 | 2025-12-16 |
| Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer Garmin Vivofit Activity Tracker - Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III | Not applicable | Terminated | NRG Oncology | 3 | 2021-08-26 | 2026-05-08 |
| Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy - Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I | Phase 2 | Suspended | Stanford University | 80 | 2021-04-08 | 2026-07-07 |
Showing 20 of 35. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (35) · Lung Neoplasms (4) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma (1) · Frailty (1) · Melanoma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Radiation Injuries (1) · Radiation Pneumonitis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Vaccinia (1)
Bronchial Neoplasms (35) · Carcinoma, Bronchogenic (35) · Lung Diseases (35) · Respiratory Tract Diseases (35) · Respiratory Tract Neoplasms (35) · Thoracic Neoplasms (35) · Neoplasms (34) · Neoplasms by Site (34) · Lung Neoplasms (31) · Neoplasms, Glandular and Epithelial (3) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Wounds and Injuries (2) · Adenocarcinoma (1) · Breast Diseases (1)
durvalumab (8) · Cisplatin (5) · Carboplatin (3) · Nivolumab (3) · Pemetrexed (3) · Radiotherapy (3) · Chemoradiotherapy (2) · Platinum Compounds (2) · Radiosurgery (2) · Surgical Procedures, Operative (2) · Vinorelbine (2) · atezolizumab (2) · pembrolizumab (2) · sintilimab (2) · 130-nm albumin-bound paclitaxel (1)
First People's Hospital of Hangzhou (4) · Fundación GECP (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · AbbVie (1) · Alexander Chi (1) · Anhui Provincial Cancer Hospital (1) · Anhui Shi, MD (1) · Ankara University (1) · Bi Nan (1) · CStone Pharmaceuticals (1) · Case Comprehensive Cancer Center (1) · Catalysis SL (1) · ETOP IBCSG Partners Foundation (1) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · Genelux Corporation (1)
China (16) · United States (8) · Spain (4) · Netherlands (2) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Kazakhstan (1) · Russia (1) · South Korea (1) · Switzerland (1) · Turkey (Türkiye) (1)
Mariano Provencio, MD (2) · Alexander Chi, MD (1) · Changli Wang (1) · Charles Simone, MD (1) · Dirk De Ruysscher, MD PhD (1) · Jie He, MD (1) · Joel W Neal, MD,PhD (1) · Joshua Reuss, MD (1) · Melinda Hsu, MD, MS (1) · Nitin Ohri, MD (1) · Qing Zhou (1) · Roberto Ferrara (1)
PMID 30150014, PMID 31641390, PMID 35038429, PMID 36027483, PMID 36268845, PMID 38718190, PMID 40421698, PMID 42201929
2014 (1), 2016 (1), 2019 (1)